

Iclusig[®] REMS

FDA REQUIRED REMS SAFETY INFORMATION

Iclusig[®] (ponatinib)

- Revised indications
- New safety information about risk of vascular occlusion
- New dosing considerations

<Date>

IMPORTANT SAFETY UPDATE

Dear Healthcare Provider:

The FDA has required this update as part of the Iclusig REMS (**R**isk **E**valuation and **M**itigation **S**trategy) to inform Healthcare Providers about the following **labeling updates** and **serious risks of Iclusig**:

• **Revised indications have been limited to:**

- Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
- Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated

• **New safety information about risk of vascular occlusion in Boxed Warning**

- Arterial and venous thrombosis and occlusions have occurred in at least **27%** of Iclusig clinical trial patients

• **New dosing considerations**

- **Optimal dosing has not been identified.** In clinical trials, the starting dose of Iclusig was 45 mg administered orally once daily. However, 59% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy

Please see the nonpromotional fact sheet, reviewed by the FDA, with more detailed safety information: [Iclusig REMS Fact Sheet](#)

You may also visit www.iclusigREMS.com for more information.

This letter does not contain the complete safety profile for Iclusig. To review the Prescribing Information, including complete Boxed Warning and Medication Guide, see links below:

[Prescribing Information](#)

[Medication Guide](#)

Iclusig[®] REMS

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Healthcare Providers should report all suspected adverse events associated with Iclusig to the FDA or to ARIAD at 1-855-552-7423 or send the information to ARIAD at medinfo@ariad.com.

Sincerely,



Frank G. Haluska, MD, PhD
Chief Medical Officer
Senior Vice President, Clinical Research and Development
ARIAD Pharmaceuticals, Inc.